Precipio sells blood-cancer diagnostic tests and patented lab tools like ICE-COLD PCR kits to hospitals and biopharma firms, acting as a niche lab-in-a-box for cancer detection. Think of it as a specialized toolkit for spotting rare cancer cells in blood sampl
Money comes from selling diagnostic tests, reagents, and PCR kits, with gross margins around 44% (TTM). But the company loses money on every sale—net margin is -4.42%—so it's not yet profitable. Revenue is recurring from repeat test orders, but the scale is to
The ICE-COLD PCR patent is a genuine technical edge—competitors like Illumina and Thermo Fisher don't have this exact sensitivity-boosting method. But the moat is eroding because the technology is niche, the market is tiny, and larger players with deeper R&D b
Key events, in time order
None yet
None yet
The user is closely watching $PRPO's strategy for sales and scale expansion, indicating a focus on fundamental growth potential.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
